Jeffrey T. Finer
Co-Founder, CEO & DirectorDr. Jeffrey T. Finer, also known as Jeff, M.D. & Ph.D., serves as Consultant of Kainomyx, Inc. He is Co-Founder & Director of Septerna, Inc. and serves as its Chief Executive Officer from September 2022 and was its President since December 2019 until August 1, 2025. He served as Interim President and interim CEO at Septerna Inc until September 2022. He has served as our President since December 2019 and as Chief Executive Officer and as a member of our board of directors since November 2021.He has helped create and launch multiple new biotech companies, including Maze Therapeutics and Ambys Medicines. He serves as Venture Partner at Third Rock Ventures, LLC. In addition to being a Co-founder of Septerna, he has held R&D leadership positions at Theravance Biopharma. Previously, he served as an Entrepreneur-in-Residence at the firm. Dr. Finer joined Third Rock Ventures, LLC in 2016 and focuses on drug discovery and development opportunities across the firm’s portfolio. He serves as Director of the Board at Strateos, Inc. He joined Strateos’s Board of Directors in May 2018. He has research, clinical and business experience including experience leading drug discovery programs, technology development initiatives, preclinical development and translational medicine to the firm. Prior to joining Third Rock, Dr. Finer spent time in research and development leadership positions at a number of biotechnology companies. From 2011 to 2016, he was at Theravance, where he served most recently as Vice President, research technology. He served as Vice President of Molecular and Cellular Biology of Innoviva, Inc from 2011 to June 2014. He has been an Independent Director of Transcriptic, Inc since May 2018. Dr. Finer served as Chairman of the Board at Strateos, Inc. until 2022. Dr. Finer served as Vice President of Discovery at Five Prime Therapeutics, Inc. from 2007 to 2011. Prior to joining FivePrime, he served as Director of Drug Discovery Technologies at Cytokinetics from 1998 to 2007 where he led a multidisciplinary team responsible for lead discovery and the development of new technologies to help speed drug discovery. Dr. Finer's team at Cytokinetics discovered lead molecules for several novel protein targets which yielded 4 drugs that entered clinical development in oncology and cardiovascular disease. His first high-tech job as a teenager was deploying the first database system used at a funeral home before realizing that he then had to populate it with 90 years of data. He has focused his career on breakthrough innovations which have included moving several first-in-class drugs into the clinic and developing novel technology platforms which integrate science, instruments, informatics and engineering and company creation. He serves on the boards of Ambys Medicines and Maze Therapeutics. He holds several patents and he has published extensively in peer-reviewed journals. He completed residency training in Internal Medicine at Stanford and in Ophthalmology at Massachusetts Eye & Ear Infirmary and Harvard Medical School. Dr. Finer received B. S. degrees in Chemistry and Biology from Massachusetts Institute of Technology (1984-1988) and he received his M. D. and Ph. D. in Biochemistry and Biophysics from Stanford University School of Medicine (1988-1995).
Positions
- Company NameSepterna, Inc.Stock CodeSEPNPositionCo-Founder, CEO & DirectorColleagues
- JKJeffrey K. TongChairman of the Board
- EPElizabeth P. BhattPresident & COO
- GMGilbert M. LabrucherieChief Financial Officer
- RJRobert J. LefkowitzCo-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board
- ACArthur ChristopoulosCo-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board
- PSPatrick SextonCo-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board
